Device Trial Radar · NCT07926945
Effects of nVNS on Stress Reactivity in IBS
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2031
Study completion Dec 1, 2031
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction that causes abdominal pain and altered bowel habits. Many people with IBS also experience symptoms outside the bowel, such as headaches, widespread pain, poor sleep, anxiety, and depression; these symptoms are especially common in females. This study focuses on stress reactivity (SR), a persistent pattern of stress-system activity that may be linked to autonomic nervous system function, immune activity, the gut microbiome, and brain processing. The investigators will enroll adults with at least moderate IBS symptoms and randomly assign them to 8 weeks of non-invasive vagal nerve stimulation (nVNS) or Usual Care. Participants assigned to nVNS will use a handheld device on the left side of the neck at home twice daily. The investigators will compare changes in IBS severity and other physical symptoms and examine whether baseline or treatment-related changes in blood, stool, heart-rate variability, sex hormones, and brain imaging measures are associated with response. The study will also explore whether treatment effects and predictors differ by sex.
Conditions
- Irritable Bowel Syndrome (IBS)
Interventions
Truvaga PlusDevice
Self-administered transcutaneous cervical nVNS device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in IBS Severity Scoring System (IBS-SSS)Time frame: 8 weeks, from baseline to end of intervention
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.